Back to Search
Start Over
Identification of biomarkers for drug-resistant endometriosis using clinical proteomics.
- Source :
- Human Cell; Mar2021, Vol. 34 Issue 2, p394-399, 6p
- Publication Year :
- 2021
-
Abstract
- Dienogest (DNG), is an effective and widely used progestin used in the treatment of endometriosis, yet clinically, a subset of cases show resistance to DNG treatment. During a previous investigation on the effect of DNG of cytokines and growth factor production, we incidentally found that endometriotic cyst fluid did not demonstrate inhibitory effects to DNG in a subset of cases. To clarify the mechanisms of this resistance to DNG, we performed proteomics analysis to compare the protein expression between DNG-sensitive and resistant cases. Based upon our results, several proteins were extracted that relate to neutrophil granulocyte activation marker (myeloperoxidase, lactotransferrin), inflammation (azurocidin, neutrophil gelatinase-associated lipocalin, etc.), and others biological processes reflecting the clinical environment of the endometriotic cyst. Among these proteins, azurocidin (AZU) is perhaps most interesting one as azurocidin is a protease that cleaves insulin-like growth factor-1 (IGFBP-1) associated with clear cell carcinoma of the ovary. We propose that the proteins extracted in the present study warrant further investigation in their relationship to carcinogenesis of endometrioma. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09147470
- Volume :
- 34
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Human Cell
- Publication Type :
- Academic Journal
- Accession number :
- 148887320
- Full Text :
- https://doi.org/10.1007/s13577-020-00465-0